Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-25T06:46:01.676Z Has data issue: false hasContentIssue false

Authors' Reply

Published online by Cambridge University Press:  02 January 2018

H. Verdoux
Affiliation:
Université Victor Segalen Bordeaux 2, Hôpital Charles Perrens, 121 rue de la Béchade, 33076 Bordeaux Cedex, France. E-mail: [email protected]
B. Bégaud
Affiliation:
Université Victor Segalen Bordeaux 2, Hôpital Charles Perrens, 121 rue de la Béchade, 33076 Bordeaux Cedex, France. E-mail: [email protected]
Rights & Permissions [Opens in a new window]

Abstract

Type
Columns
Copyright
Copyright © 2005 The Royal College of Psychiatrists 

The German findings on antipsychotic prescription in naturalistic conditions provide a good illustration of the question raised in our editorial regarding the risk of widespread use of antipsychotics in primary care (Reference Verdoux and BegaudVerdoux & Bégaud, 2004). Contrary to the statement of the author, there is no contradiction between her point of view and ours regarding the fact that antipsychotics are widely prescribed in primary care. The exact quotation of our text is ‘drugs assumed to be mainly prescribed by specialists, such as antipsychotics’, suggesting that there may be differences between assumptions and facts. The German findings are strikingly similar to those obtained using the social security insurance database in Aquitaine (south-west France), showing that general practitioners (GPs) were the most numerous prescribers (64%) of risperidone, followed by psychiatrists (34%) (Reference Martin, Bégaud and VerdouxMartin et al, 2004). More recently, we have carried out a survey questionnaire mailed to all GPs (n = 3829) practising in Aquitaine to explore management of early psychosis in primary care, with a response rate of 23% (further details available from the authors on request). As part of this survey, we collected data on prescription behaviour. We found that over the preceding month, one out of three GPs (34%) initiated at least one new treatment with one of the antipsychotic drugs marketed in France at this time (amisulpride, olanzapine, risperidone). Over the same 1-month period, nearly half of GPs (42%) reported a visit from at least one pharmaceutical company representative promoting these antipsychotic drugs. Hence, we have further reason to feel concerned by the widespread use of these drugs in primary care, probably, at least in part, as a result of drug promotion. As proposed by Thiels, it is thus of great interest to explore which specific subgroups are at greater risk of being exposed to increased use of antipsychotics. With respect to the hypothesis that there may be a trend favouring antipsychotic instead of benzodiazepine prescription in elderly patients, it is however difficult to conclude that such a strategy is more risky than beneficial for this population, considering the risks potentially associated with benzodiazepine prescription in the elderly (Reference Verdoux, Lagnaoul and BégaudVerdoux et al, 2004).

Footnotes

EDITED BY KHALIDA ISMAIL

Declaration of interest

H. V. has acted as a consultant to the pharmaceutical companies. Bristol-Myers-Squibb, Eli Lilly, Janssen-Cilag, Lundbeck and. Sanofi-Synthélabo.

References

Martin, K., Bégaud, B., Verdoux, H., et al (2004) Patterns of risperidone prescription: a utilization study in south-west France. Acta Psychiatrica Scandinavica, 109, 202206.CrossRefGoogle ScholarPubMed
Verdoux, H. & Begaud, B. (2004) Pharmaco-epidemiology: what do (and don't) we know about utilisation and impact of psychotropic medications in real-life conditions? British Journal of Psychiatry, 185, 9394.Google Scholar
Verdoux, H., Lagnaoul, R. & Bégaud, B. (2004) Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies. Psychological Medicine, 35, 19.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.